Key result
Daily administration of pioglitazone (3 mg/kg) in fructose-fed Wistar fatty rats normalized triglyceride levels to 1.18 mmol/l by increasing their ability to remove VLDL-TG from the circulation.
Why the study?
Does pioglitazone improve VLDL-triglyceride kinetics and metabolic parameters in fructose-fed Wistar fatty rats?
Population
Genetically obese Wistar fatty rats characterized by hyperinsulinemia, hyperglycemia, and…
Comparison
Dietary fructose alone or in combination with… vs Lean rats, and untreated Wistar fatty rats
Design
Preclinical
Authors
Loading...
Hypothesis-generating for pioglitazone in human hypertriglyceridemia; should not change clinical practice.
Does pioglitazone improve VLDL-triglyceride kinetics and metabolic parameters in fructose-fed Wistar fatty rats?
Pioglitazone normalizes hypertriglyceridemia in an insulin-resistant rat model by improving VLDL-triglyceride clearance rather than reducing its hepatic production.
Kazumi et al. (1996) studied NIDDM (animal model). Dietary fructose and pioglitazone vs. Lean rats and untreated fatty rats was evaluated on VLDL-triglyceride (TG) turnover and TG levels. Daily administration of pioglitazone (3 mg/kg) in fructose-fed Wistar fatty rats normalized triglyceride levels to 1.18 mmol/l by increasing their ability to remove VLDL-TG from the circulation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: